Lonza has expanded its highly potent API (HPAPI) capacity to support antibody drug conjugate (ADC) payload manufacturing. This HPAPI expansion encompasses two new manufacturing suites capable of handling compounds with occupational exposure levels down to 1ng/m3. The strategic ADC expansion allows the company to develop and produce all components of this growing cancer treatment: cytotoxic payloads, antibodies and the required linkers. The HPAPI and ADC payload expansion is expected to be on-lin...